Journal Club #2: Omega-3 Fatty Acids for MDD Treatment (ISNPR Practice Guidelines)
Today we posted the following second journal club in PEFA Journal Club’s discussion series:
Journal Club #2:
International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder.
Article: Psychother Psychosom. 2019;88(5):263-273.
This 25 minutes journal club video discussion will answer the following 10 clinically relevant questions:
- Are omega-3 fatty acids effective as augmentation or as monotherapy for MDD management?
- What dose of omega-3 fatty acid is considered therapeutic for the treatment of MDD?
- What ratio of EPA/DHA is crucial for omega-3 fatty acids’s therapeutic benefit?
- Is pure EHA more efficacious than the combination of EHA/DHA for MDD?
- What is the recommended minimum duration of treatment with omega-3 fatty acid for the treatment of MDD?
- Is omega-3 fatty acid efficacious for recurrent depression?
- What are the common adverse events at the therapeutic dose of omega-3 fatty acid?
- What additional lab work is required when using the higher dosages of omega-3 fatty acid?
- How to ensure the omega-3 fatty acid’s product quality before buying?
- Do omega-3 fatty acid’s response in MDD have a relation with inflammatory biomarkers?
FOR PEFA MEMBERS ONLY:
Psychiatry Education Forum’s Journal Club is an additional feature for PEF Academy’s members. All academy members will be automatically enrolled in this journal club.
Here we post the most recently published psychiatry articles relevant to your daily clinical practice with CME credits available for selective journal club activities.
PEFA Journal Club’s updated schedule (from June 13 to June 24, 2021) will contain the following 13 clinically relevant topics discussion & access to 4.75 AMA PRA Category 1 CME Credits (available from June 26, 2021).
MAJOR DEPRESSIVE DISORDER: GUIDELINES UPDATE
Journal Club #1: (June 13, 2021)
Update on Nonpsychotic Unipolar Depression: Psychopharmacology Algorithm Project.
Psychother Psychosom. 2019;88(5):263-273
Journal Club #2: (June 14, 2021)
Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder.
Psychother Psychosom. 2019;88(5):263-273
BIPOLAR DISORDER: GUIDELINES UPDATE
Journal Club #3: (June 15, 2021)
Bipolar Depression Update: CANMAT & ISBD (2018) Vs Psychopharmacology Algorithm Project Update (2019) Guidelines
Harv Rev Psychiatry. 2010 Jan-Feb;18(1):36-55.5
SCHIZOPHRENIA
Journal Club #4: (June 16, 2021)
Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study.
Int J Neuropsychopharmacol. 2019 Nov 1;22(11):681-697
Journal Club #5: (June 17, 2021)
Comparing 32 Oral Antipsychotics for Acute Multi-Episode Schizophrenia Treatment.
Lancet. 2019;394(10202):939-951.
Journal Club #6: (June 18, 2021)
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: Randomized Clinical Trial.
JAMA Psychiatry . 2020 Apr 1;77(4):349-358.
Journal Club #7: (June 18, 2021)
Non-D2-Receptor-Binding Medication for Schizophrenia.
N Engl J Med. 2020 Apr 16;382(16):1497-1506.
PSYCHOPHARMACOLOGY: ADVERSE EVENTS
Journal Club #8: (June 19, 2021)
Vortioxetine for Emotional Blunting in patients with Inadequate Response to SSRI/SNRI.
Psychother Psychosom. 2019;88(5):263-273
Journal Club #9: (June 20, 2021)
Adjunctive Metformin for Antipsychotic-Induced Dyslipidemia: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials.
Transl Psychiatry. 2020 Apr 23;10(1):117.
Journal Club #10: (June 21, 2021)
Almost all Antipsychotics Result in Weight Gain: Meta-Analysis.
PLoS One. 2014 Apr 24;9(4):e94112
PSYCHOPHARMACOLOGY: SAFETY RISKS
Journal Club #11: (June 22, 2021)
Associations of Benzodiazepines, Z-Drugs, and Other Anxiolytics With Subsequent Dementia in Patients With Affective Disorders
Am J Psychiatry. 2020 Jun 1;177(6):497-505.
Journal Club #12: (CME Credits not Available for this Journal Club): June 23, 2021
Is Ketamine Safe with History of Psychosis?
JAMA Network Open. 2020 May; 3(5): e204693
PTSD (POST-TRAUMATIC STRESS DISORDER)
Journal Club #13: (June 24, 2021)
International Trauma Questionnaire to assess Post-Traumatic Stress Disorder (PTSD) & Complex PTSD.
Br J Psychiatry. 2020;216(3):132‐137.
CME ACCREDITATION:
4.75 AMA PRA Category 1 Credits Available from June 26, 2021
→ CME Credits will increase with our upcoming journal club video discussions.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute, LLC and Psychiatry Education Forum LLC. The PeerPoint Medical Education Institute, LLC is accredited by the ACCME to provide continuing medical education for physicians.
The PeerPoint Medical Education Institute, LLC designates this enduring activity for a maximum of 4.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Accreditation & Designation Statements and Disclosure Report:
INTERESTED IN JOINING THIS JOURNAL CLUB DISCUSSION SERIES?
JOIN PSYCHIATRY EDUCATION FORUM ACADEMY MEMBERSHIP
This is a closed membership for medical professionals only.
- 30+ Courses/Sections: Each chapter within these sections is of direct clinical relevance for your daily practice.
- Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice.
- Coffee Club: contain short discussions with clinical experts in the field of psychiatry.
- Essentials of Inpatient Psychiatry Book: All chapters from this book are included in the academy sections.
- Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases.
- Conference Discounts: Academy members get discounted access at our conferences.
- Goal: is to have all important clinically relevant topics in one place for ease of access.
SUBSCRIBE TO OUR EMAIL NEWSLETTER:
